Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.79 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.52 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6330218 | 0.94 | KDR (0.79) | KDRROCK1LIMK1LIMK2NAMPT | |
| SCHEMBL3651635 | 0.89 | KDR (1.00) | KDRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3596386 | 0.81 | KDR (0.72) | KDRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3605321 | 0.80 | KDR (0.58) | KDRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6330404 | 0.79 | KDR (1.00) | KDRROCK1LIMK1NAMPT | |
| SCHEMBL20380021 | 0.78 | KDR (0.79) | KDRROCK1NAMPT | |
| SCHEMBL6332623 | 0.78 | KDR (0.79) | KDRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3596194 | 0.78 | KDR (0.51) | KDRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL20379918 | 0.78 | KDR (0.72) | KDRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3602543 | 0.77 | VCP (0.58) | KDRMAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| CN-1902186-B | Thiazole and pyrazole derivatives as FLT-3 kinase inhibitors | NOVARTIS AG | 2010-12-22 | — | — | CN | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| CN-1902186-A | Thiazole and pyrazole derivatives as FLT-3 kinase inhibitors | NOVARTIS AG (CH) | 2007-01-24 | — | — | CN | disclosed |
| EP-1687285-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047273-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | FLT3, FLT1, FLT4 | KDR 8/4885MAPK13 611/4885MAPK12 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.